Biotech | March 07, 2022
HCmed, Formosa Laboratories, and Formosa Pharmaceuticals form CDMO
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
_256_384.jpg)
In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Subscribe To Our Newsletter & Stay Updated
